# Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878 - Ireland

# **SAFETY DATA SHEET**



ALPOLAN DUOFINISH 5461-80 - FARBLOS-INCOLORE-COLOURLESS

### SECTION 1: Identification of the substance/mixture and of the company/ undertaking

### 1.1 Product identifier

**Product name** 

: ALPOLAN DUOFINISH 5461-80 - FARBLOS-INCOLORE-COLOURLESS

**1.2 Relevant identified uses of the substance or mixture and uses advised againstProduct use**: Paint.

#### 1.3 Details of the supplier of the safety data sheet

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

e-mail address of person : Prod-safe@teknos.com

### responsible for this SDS

National contact

Teknos Group Oy, Takkatie 3, FI-00370 HELSINKI, FINLAND. Tel. +358 9 506 091.

### 1.4 Emergency telephone number

#### National advisory body/Poison Centre

Telephone number : National Poisons Information Centre: 01 809 2566

### **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

Product definition : Mixture

Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 2, H225 Skin Irrit. 2, H315 Eye Irrit. 2, H319 Skin Sens. 1, H317 Repr. 2, H361d STOT SE 3, H336 STOT RE 2, H373

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

See Section 16 for the full text of the H statements declared above.

See Section 11 for more detailed information on health effects and symptoms.

#### 2.2 Label elements

**Hazard pictograms** 



Signal word Hazard statements

#### : Danger

: H225 - Highly flammable liquid and vapour.

- H315 Causes skin irritation.
- H317 May cause an allergic skin reaction.
- H319 Causes serious eye irritation.
- H336 May cause drowsiness or dizziness.
- H361d Suspected of damaging the unborn child.
- H373 May cause damage to organs through prolonged or repeated exposure.

#### **Precautionary statements**

| Date of issue/Date of revision | : 26/09/2024 | Date of previous issue | : No previous validation | Version  | :1     | 1/20 |
|--------------------------------|--------------|------------------------|--------------------------|----------|--------|------|
| ALPOLAN DUOFINISH 5461-80 -    | FARBLOS-II   | NCOLORE-COLOURLESS     |                          | Label No | :51674 | 4    |

## **SECTION 2: Hazards identification**

| Prevention  | : | <ul> <li>P280 - Wear protective gloves, protective clothing, eye protection, face protection, or hearing protection.</li> <li>P210 - Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking.</li> <li>P260 - Do not breathe vapour.</li> </ul> |
|---|---|---|
| Response  | : | P314 - Get medical advice/attention if you feel unwell.   |
| Storage   | : | P403 + P233 - Store in a well-ventilated place. Keep container tightly closed.  |
| Disposal  | 1 | P501 - Dispose of contents and container in accordance with all local, regional, national and international regulations.  |
| Hazardous ingredients   | 1 | Contains: n-Butyl acetate; Toluene; Methyl methacrylate and EO bis(benztriazolyl) phenylpropionat   |
| Supplemental label elements   | 1 |   |
| Annex XVII - Restrictions<br>on the manufacture,<br>placing on the market and<br>use of certain dangerous<br>substances, mixtures and<br>articles | : |   |
| 2.3 Other hazards   |   |   |
| Product meets the criteria<br>for PBT or vPvB according<br>to Regulation (EC) No.<br>1907/2006, Annex XIII  | : | This mixture does not contain any substances that are assessed to be a PBT or a vPvB.   |
| Other hazards which do  | 1 | None known.   |

not result in classification

## **SECTION 3: Composition/information on ingredients**

| Product/ingredient name | Identifiers  | %         | Classification   | Specific Conc.<br>Limits, M-factors<br>and ATEs                             | Туре    |
|-------------------------|--|-----------|--|---|---------|
| n-Butyl acetate         | REACH #:<br>01-2119485493-29<br>EC: 204-658-1<br>CAS: 123-86-4<br>Index: 607-025-00-1  | ≥25 - ≤50 | Flam. Liq. 3, H226<br>STOT SE 3, H336<br>EUH066  | -   | [1] [2] |
| Ethyl acetate           | REACH #:<br>01-2119475103-46<br>EC: 205-500-4<br>CAS: 141-78-6<br>Index: 607-022-00-5  | ≥10 - ≤25 | Flam. Liq. 2, H225<br>Eye Irrit. 2, H319<br>STOT SE 3, H336<br>EUH066  | -   | [1] [2] |
| Toluene                 | REACH #:<br>01-2119471310-51<br>EC: 203-625-9<br>CAS: 108-88-3<br>Index: 601-021-00-3  | ≥10 - ≤25 | Flam. Liq. 2, H225<br>Skin Irrit. 2, H315<br>Repr. 2, H361d<br>STOT SE 3, H336<br>STOT RE 2, H373<br>Asp. Tox. 1, H304   | -   | [1] [2] |
| Xylene                  | REACH #:<br>01-2119488216-32<br>EC: 215-535-7<br>CAS: 1330-20-7<br>Index: 601-022-00-9 | <10       | Flam. Liq. 3, H226<br>Acute Tox. 4, H312<br>Acute Tox. 4, H332<br>Skin Irrit. 2, H315<br>Eye Irrit. 2, H319<br>STOT SE 3, H335<br>STOT RE 2, H373<br>(oral, inhalation)<br>Asp. Tox. 1, H304 | ATE [Dermal] =<br>1100 mg/kg<br>ATE [Inhalation<br>(vapours)] = 11 mg/<br>I | [1] [2] |

| 2-butoxyethyl acetate                    | REACH #:<br>01-2119475112-47<br>EC: 203-933-3<br>CAS: 112-07-2<br>Index: 607-038-00-2    | ≤3   | Acute Tox. 4, H312<br>Acute Tox. 4, H332   | ATE [Dermal] =<br>1500 mg/kg<br>ATE [Inhalation<br>(vapours)] = 11 mg/<br>I | [1] [2] |
|--|--|------|--|---|---------|
| Ethylbenzene                             | REACH #:<br>01-2119489370-35<br>EC: 202-849-4<br>CAS: 100-41-4<br>Index: 601-023-00-4    | ≤3   | Flam. Liq. 2, H225<br>Acute Tox. 4, H332<br>STOT RE 2, H373<br>(hearing organs) (oral,<br>inhalation)<br>Asp. Tox. 1, H304 | ATE [Inhalation<br>(vapours)] = 11 mg/<br>I                                 | [1] [2] |
| Methyl methacrylate                      | REACH #:<br>01-2119452498-28<br>EC: 201-297-1<br>CAS: 80-62-6<br>Index: 607-035-00-6     | ≤0.3 | Flam. Liq. 2, H225<br>Skin Irrit. 2, H315<br>Skin Sens. 1, H317<br>STOT SE 3, H335   | -   | [1] [2] |
| EO bis(benztriazolyl)<br>phenylpropionat | REACH #:<br>01-0000015075-76<br>EC: 400-830-7<br>CAS: 104810-48-2<br>Index: 607-176-00-3 | ≤0.3 | Skin Sens. 1A, H317<br>Aquatic Chronic 2,<br>H411  | -   | [1]     |
|  |  |      | See Section 16 for<br>the full text of the H<br>statements declared<br>above.  |   |         |

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section.

Туре

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

Occupational exposure limits, if available, are listed in Section 8.

### **SECTION 4: First aid measures**

| 4.1 Description of first aid m | easures   |
|--------------------------------|---|
| Eye contact                    | : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention.   |
| Inhalation                     | : Remove victim to fresh air and keep at rest in a position comfortable for breathing.<br>If it is suspected that fumes are still present, the rescuer should wear an appropriate<br>mask or self-contained breathing apparatus. If not breathing, if breathing is irregular<br>or if respiratory arrest occurs, provide artificial respiration or oxygen by trained<br>personnel. It may be dangerous to the person providing aid to give mouth-to-mouth<br>resuscitation. Get medical attention. If necessary, call a poison center or physician.<br>If unconscious, place in recovery position and get medical attention immediately.<br>Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or<br>waistband. In case of inhalation of decomposition products in a fire, symptoms may<br>be delayed. The exposed person may need to be kept under medical surveillance<br>for 48 hours. |
| Skin contact                   | : Wash with plenty of soap and water. Remove contaminated clothing and shoes.<br>Wash contaminated clothing thoroughly with water before removing it, or wear<br>gloves. Continue to rinse for at least 10 minutes. Get medical attention. In the<br>event of any complaints or symptoms, avoid further exposure. Wash clothing before<br>reuse. Clean shoes thoroughly before reuse.   |

### SECTION 4: First aid measures

| Ingestion                  | : Wash out mouth with water. Remove dentures if any. If material has been<br>swallowed and the exposed person is conscious, give small quantities of water to<br>drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not<br>induce vomiting unless directed to do so by medical personnel. If vomiting occurs,<br>the head should be kept low so that vomit does not enter the lungs. Get medical<br>attention. If necessary, call a poison center or physician. Never give anything by<br>mouth to an unconscious person. If unconscious, place in recovery position and get<br>medical attention immediately. Maintain an open airway. Loosen tight clothing such<br>as a collar, tie, belt or waistband. |
|----------------------------|---|
| Protection of first-aiders | : No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Wash contaminated clothing   |

thoroughly with water before removing it, or wear gloves.

### 4.2 Most important symptoms and effects, both acute and delayed

| Eye contact  | : Adverse symptoms may include the following:<br>pain or irritation<br>watering<br>redness  |
|--------------|---|
| Inhalation   | : Adverse symptoms may include the following:<br>nausea or vomiting<br>headache<br>drowsiness/fatigue<br>dizziness/vertigo<br>unconsciousness<br>reduced foetal weight<br>increase in foetal deaths<br>skeletal malformations |
| Skin contact | : Adverse symptoms may include the following:<br>irritation<br>redness<br>reduced foetal weight<br>increase in foetal deaths<br>skeletal malformations  |
| Ingestion    | : Adverse symptoms may include the following:<br>reduced foetal weight<br>increase in foetal deaths<br>skeletal malformations   |

# 4.3 Indication of any immediate medical attention and special treatment needed Notes to physician In case of inhalation of decomposition products in a fire, symptoms may be delayed. The exposed person may need to be kept under medical surveillance for 48 hours. Specific treatments No specific treatment.

### **SECTION 5: Firefighting measures**

| 5.1 Extinguishing media<br>Suitable extinguishing<br>media | : Use dry chemical, CO <sub>2</sub> , water spray (fog) or foam. |
|--|--|
| Unsuitable extinguishing media                             | : Do not use water jet.  |

### 5.2 Special hazards arising from the substance or mixture

| Hazards from the     | 1 | Highly flammable liquid and vapour. Runoff to sewer may create fire or explosion     |
|----------------------|---|--|
| substance or mixture |   | hazard. In a fire or if heated, a pressure increase will occur and the container may |
|                      |   | burst, with the risk of a subsequent explosion.                                      |

| Date of issue/Date of revision | : 26/09/2024 | Date of previous issue | : No previous validation | Version  | :1   | 4/20 |
|--------------------------------|--------------|------------------------|--------------------------|----------|------|------|
| ALPOLAN DUOFINISH 5461-80 -    | FARBLOS-IN   | NCOLORE-COLOURLESS     |                          | Label No | 5167 | 4    |

| SECTION 5: Firefighting measures                  |   |  |  |  |
|---|---|--|--|--|
| Hazardous combustion products                     | : Decomposition products may include the following materials:<br>carbon dioxide<br>carbon monoxide<br>nitrogen oxides   |  |  |  |
| 5.3 Advice for firefighters                       |   |  |  |  |
| Special protective actions for fire-fighters      | : Promptly isolate the scene by removing all persons from the vicinity of the incident if there is a fire. No action shall be taken involving any personal risk or without suitable training. Move containers from fire area if this can be done without risk. Use water spray to keep fire-exposed containers cool.                                      |  |  |  |
| Special protective<br>equipment for fire-fighters | : Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full face-piece operated in positive pressure mode. Clothing for fire-fighters (including helmets, protective boots and gloves) conforming to European standard EN 469 will provide a basic level of protection for chemical incidents. |  |  |  |

### **SECTION 6: Accidental release measures**

#### 6.1 Personal precautions, protective equipment and emergency procedures

| For non-emergency<br>personnel | : | No action shall be taken involving any personal risk or without suitable training.<br>Evacuate surrounding areas. Keep unnecessary and unprotected personnel from<br>entering. Do not touch or walk through spilt material. Shut off all ignition sources.<br>No flares, smoking or flames in hazard area. Avoid breathing vapour or mist.<br>Provide adequate ventilation. Wear appropriate respirator when ventilation is<br>inadequate. Put on appropriate personal protective equipment. |
|--------------------------------|---|--|
| For emergency responders       | : | If specialised clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".  |
| 6.2 Environmental precautions  | : | Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental  |

pollution (sewers, waterways, soil or air).

#### 6.3 Methods and material for containment and cleaning up

| Small spill                     | : Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.   |
|---------------------------------|--|
| Large spill                     | : Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach the release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with non-combustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilt product. |
| 6.4 Reference to other sections | : See Section 1 for emergency contact information.<br>See Section 8 for information on appropriate personal protective equipment.<br>See Section 13 for additional waste treatment information.  |

### **SECTION 7: Handling and storage**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

### 7.1 Precautions for safe handling

### **SECTION 7: Handling and storage**

|  | 5 5  |
|--|--|
| Protective measures                    | : Put on appropriate personal protective equipment (see Section 8). Persons with a history of skin sensitization problems should not be employed in any process in which this product is used. Avoid exposure - obtain special instructions before use. Avoid exposure during pregnancy. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not breathe vapour or mist. Do not ingest. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container. |
| Advice on general occupational hygiene | : Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.  |

#### 7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Eliminate all ignition sources. Separate from oxidising materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabelled containers. Use appropriate containment to avoid environmental contamination.

### Seveso Directive - Reporting thresholds

| Danger criteria |                                 |                         |  |  |  |
|-----------------|---------------------------------|-------------------------|--|--|--|
|                 | Notification and MAPP threshold | Safety report threshold |  |  |  |
| P5c             | 5000 tonne                      | 50000 tonne             |  |  |  |

#### 7.3 Specific end use(s)

# **Recommendations**

: Not available.

Industrial sector specific solutions

: Not available.

### SECTION 8: Exposure controls/personal protection

ALPOLAN DUOFINISH 5461-80 - FARBLOS-INCOLORE-COLOURLESS

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

### 8.1 Control parameters

### **Occupational exposure limits**

| Product/ingredient             | name Exposure limit values  |
|--------------------------------|---|
| n-Butyl acetate                | NAOSH (Ireland, 5/2021). Notes: EU derived Occupational                       |
|                                | Exposure Limit Values   |
|                                | OELV-8hr: 50 ppm 8 hours.   |
|                                | OELV-8hr: 241 mg/m <sup>3</sup> 8 hours.                                      |
|                                | OELV-15min: 150 ppm 15 minutes.   |
|                                | OELV-15min: 723 mg/m <sup>3</sup> 15 minutes.                                 |
| Ethyl acetate                  | NAOSH (Ireland, 5/2021). Notes: EU derived Occupational                       |
|                                | Exposure Limit Values   |
|                                | OELV-8hr: 200 ppm 8 hours.  |
|                                | OELV-15min: 400 ppm 15 minutes.   |
|                                | OELV-15min: 1468 mg/m <sup>3</sup> 15 minutes.                                |
|                                | OELV-8hr: 734 mg/m <sup>3</sup> 8 hours.                                      |
| Toluene                        | NAOSH (Ireland, 5/2021). Absorbed through skin. Notes: EU                     |
|                                |   |
| Date of issue/Date of revision | : 26/09/2024 Date of previous issue : No previous validation Version : 1 6/20 |

Label No :51674

|                         | derived Occupational Exposure Limit Values                  |
|-------------------------|---|
|                         | OELV-8hr: 50 ppm 8 hours.                                   |
|                         | OELV-8hr: 192 mg/m <sup>3</sup> 8 hours.                    |
|                         | OELV-15min: 100 ppm 15 minutes.                             |
|                         | OELV-15min: 384 mg/m <sup>3</sup> 15 minutes.               |
| Xylene                  | NAOSH (Ireland, 5/2021). [xylene mixed isomers] Absorbed    |
| ,                       | through skin. Notes: EU derived Occupational Exposure Limit |
|                         | Values  |
|                         | OELV-8hr: 50 ppm 8 hours.                                   |
|                         | OELV-8hr: 221 mg/m <sup>3</sup> 8 hours.                    |
|                         | OELV-15min: 100 ppm 15 minutes.                             |
|                         | OELV-15min: 442 mg/m <sup>3</sup> 15 minutes.               |
| 2-butoxyethyl acetate   | NAOSH (Ireland, 5/2021). Absorbed through skin. Notes: EU   |
|                         | derived Occupational Exposure Limit Values                  |
|                         | OELV-8hr: 20 ppm 8 hours.                                   |
|                         | OELV-8hr: 133 mg/m <sup>3</sup> 8 hours.                    |
|                         | OELV-15min: 50 ppm 15 minutes.                              |
|                         | OELV-15min: 333 mg/m <sup>3</sup> 15 minutes.               |
| Ethylbenzene            | NAOSH (Ireland, 5/2021). Absorbed through skin. Notes: EU   |
|                         | derived Occupational Exposure Limit Values                  |
|                         | OELV-8hr: 100 ppm 8 hours.                                  |
|                         | OELV-8hr: 442 mg/m <sup>3</sup> 8 hours.                    |
|                         | OELV-15min: 200 ppm 15 minutes.                             |
| Martha Las alla surdada | OELV-15min: 884 mg/m <sup>3</sup> 15 minutes.               |
| Methyl methacrylate     | NAOSH (Ireland, 5/2021). Sensitization potential. Notes: EU |
|                         | derived Occupational Exposure Limit Values                  |
|                         | OELV-8hr: 50 ppm 8 hours.                                   |
|                         | OELV-15min: 100 ppm 15 minutes.                             |

### **Biological exposure indices**

| Product/ingredient name | Exposure indices  |
|-------------------------|---|
| Toluene                 | NAOSH (Ireland, 1/2011)<br>BMGV: 0.3 mg/g creatinine, o-cresol [in urine]. Sampling time:<br>end of shift - As soon as possible after exposure ceases.<br>BMGV: 0.03 mg/l, toluene [in urine]. Sampling time: end of shift -<br>As soon as possible after exposure ceases.<br>BMGV: 0.02 mg/l, toluene [in blood]. Sampling time: prior to last<br>shift of workweek.   |
| Xylene                  | NAOSH (Ireland, 1/2011) [Xylene]<br>BMGV: 1.5 g/g creatinine, methylhippuric acids [in urine].<br>Sampling time: end of shift - As soon as possible after exposure<br>ceases.   |
| Ethylbenzene            | <ul> <li>NAOSH (Ireland, 1/2011)</li> <li>BMGV: Semi-quantitative, the biological analyte is an indicator of exposure to the substance but the quantitative interpretation of the measurement is ambiguous. These analytes should be used as a screening test if a quantitative test is not practical; or as a confirmatory test if the quantitative test is not specific and the origin of the determinant is in question., ethylbenzene [in endexhaled air]. Sampling time: not critical.</li> <li>BMGV: 0.7 g/g creatinine [Semi-quantitative, the biological analyte is an indicator of exposure to the substance but the quantitative interpretation of the measurement is ambiguous. These analytes should be used as a screening test if a quantitative test is not practical; or as a confirmatory test if the quantitative test is not practical; or as a confirmatory test if a quantitative test is not specific and the origin of the determinant is in question.], mandelic acid and phenylglyoxylic acid [in urine]. Sampling time: end of shift at end of workweek.</li> </ul> |

### **SECTION 8: Exposure controls/personal protection**

procedures

**Recommended monitoring** : Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

### **DNELs/DMELs**

| Product/ingredient name | Туре | Exposure                 | Value                        | Population            | Effects  |
|-------------------------|------|--------------------------|------------------------------|-----------------------|----------|
| -Butyl acetate          | DNEL | Short term Oral          | 2 mg/kg<br>bw/day            | General population    | Systemic |
|                         | DNEL | Long term Oral           | 2 mg/kg<br>bw/day            | General<br>population | Systemic |
|                         | DNEL | Short term Dermal        | 6 mg/kg                      | General               | Systemic |
|                         | DNEL | Short term Dermal        | bw/day<br>11 mg/kg<br>bw/day | population<br>Workers | Systemic |
|                         | DNEL | Long term<br>Inhalation  | 35.7 mg/m <sup>3</sup>       | General<br>population | Local    |
|                         | DNEL | Short term<br>Inhalation | 300 mg/m <sup>3</sup>        | General<br>population | Local    |
|                         | DNEL | Short term<br>Inhalation | 300 mg/m <sup>3</sup>        | General<br>population | Systemic |
|                         | DNEL | Long term<br>Inhalation  | 300 mg/m <sup>3</sup>        | Workers               | Local    |
|                         | DNEL | Short term<br>Inhalation | 600 mg/m³                    | Workers               | Local    |
|                         | DNEL | Short term<br>Inhalation | 600 mg/m³                    | Workers               | Systemic |
|                         | DNEL | Long term Dermal         | 3.4 mg/kg<br>bw/day          | General<br>population | Systemic |
|                         | DNEL | Long term Dermal         | 7 mg/kg<br>bw/day            | Workers               | Systemic |
|                         | DNEL | Long term<br>Inhalation  | 12 mg/m <sup>3</sup>         | General<br>population | Systemic |
|                         | DNEL | Long term<br>Inhalation  | 48 mg/m³                     | Workers               | Systemic |
| Ethyl acetate           | DNEL | Long term Oral           | 4.5 mg/kg<br>bw/day          | General<br>population | Systemic |
|                         | DNEL | Long term Dermal         | 37 mg/kg<br>bw/day           | General population    | Systemic |
|                         | DNEL | Long term Dermal         | 63 mg/kg<br>bw/day           | Workers               | Systemic |
|                         | DNEL | Long term<br>Inhalation  | 367 mg/m <sup>3</sup>        | General<br>population | Local    |
|                         | DNEL | Long term<br>Inhalation  | 367 mg/m³                    | General population    | Systemic |
|                         | DNEL | Short term<br>Inhalation | 734 mg/m³                    | General population    | Local    |
|                         | DNEL | Short term<br>Inhalation | 734 mg/m³                    | General population    | Systemic |
|                         | DNEL | Long term<br>Inhalation  | 734 mg/m <sup>3</sup>        | Workers               | Local    |
|                         | DNEL | Long term<br>Inhalation  | 734 mg/m³                    | Workers               | Systemic |
|                         | DNEL | Short term<br>Inhalation | 1468 mg/<br>m³               | Workers               | Local    |
|                         | DNEL | Short term<br>Inhalation | 1468 mg/<br>m <sup>3</sup>   | Workers               | Systemic |
| oluene                  | DNEL | Long term Oral           | 8.13 mg/<br>kg bw/day        | General<br>population | Systemic |

Da

ALPOLAN DUOFINISH 5461-80 - FARBLOS-INCOLORE-COLOURLESS

| CTION 8: Exposure     | DNEL  | Long term                               | 56.5 mg/m <sup>3</sup> | General    | Local      |  |
|-----------------------|-------|---|------------------------|------------|------------|--|
|                       | DINEL | Inhalation                              | 50.5 mg/m              | population | LUCai      |  |
|                       | DNEL  | Long term                               | 56.5 mg/m <sup>3</sup> | General    | Systemic   |  |
|                       | DINLL | Inhalation                              | 50.5 mg/m              | population | Oysternic  |  |
|                       | DNEL  | Long term                               | 192 mg/m <sup>3</sup>  | Workers    | Local      |  |
|                       | DINEL | Inhalation                              | 192 mg/m               | WUREIS     | LUCAI      |  |
|                       | DNEL  |   | $102  mg/m^3$          | Workers    | Systemic   |  |
|                       | DNEL  | Long term                               | 192 mg/m <sup>3</sup>  | vvorkers   | Systemic   |  |
|                       | DNEL  | Inhalation                              | 226 malka              | Conorol    | Svetomio   |  |
|                       | DNEL  | Long term Dermal                        | 226 mg/kg              | General    | Systemic   |  |
|                       |       | Chart tarma                             | bw/day                 | population |            |  |
|                       | DNEL  | Short term                              | 226 mg/m <sup>3</sup>  | General    | Local      |  |
|                       |       | Inhalation                              | 000 / 3                | population |            |  |
|                       | DNEL  | Short term                              | 226 mg/m <sup>3</sup>  | General    | Systemic   |  |
|                       |       | Inhalation                              |                        | population |            |  |
|                       | DNEL  | Long term Dermal                        | 384 mg/kg              | Workers    | Systemic   |  |
|                       |       |   | bw/day                 |            |            |  |
|                       | DNEL  | Short term                              | 384 mg/m³              | Workers    | Local      |  |
|                       |       | Inhalation                              |                        |            |            |  |
|                       | DNEL  | Short term                              | 384 mg/m³              | Workers    | Systemic   |  |
|                       |       | Inhalation                              |                        |            |            |  |
| Xylene                | DNEL  | Long term                               | 65.3 mg/m <sup>3</sup> | General    | Local      |  |
|                       |       | Inhalation                              |                        | population |            |  |
|                       | DNEL  | Short term                              | 260 mg/m <sup>3</sup>  | General    | Local      |  |
|                       |       | Inhalation                              | _                      | population |            |  |
|                       | DNEL  | Short term                              | 260 mg/m <sup>3</sup>  | General    | Systemic   |  |
|                       |       | Inhalation                              | Ũ                      | population | ,          |  |
|                       | DNEL  | Long term                               | 221 mg/m <sup>3</sup>  | Workers    | Local      |  |
|                       |       | Inhalation                              | J                      |            |            |  |
|                       | DNEL  | Long term Oral                          | 12.5 mg/               | General    | Systemic   |  |
|                       | 0.122 | Long tonn ordi                          | kg bw/day              | population | eyetenne   |  |
|                       | DNEL  | Long term                               | 65.3 mg/m <sup>3</sup> | General    | Systemic   |  |
|                       | DIVLL | Inhalation                              | 00.0 mg/m              | population | Cysternio  |  |
|                       | DNEL  | Long term Dermal                        | 125 mg/kg              | General    | Systemic   |  |
|                       | DINLL | Long term Derma                         | bw/day                 | population | Systemic   |  |
|                       |       |   |                        |            | Curatanaia |  |
|                       | DNEL  | Long term Dermal                        | 212 mg/kg              | Workers    | Systemic   |  |
|                       |       | 1                                       | bw/day                 | 14/        |            |  |
|                       | DNEL  | Long term                               | 221 mg/m³              | Workers    | Systemic   |  |
|                       |       | Inhalation                              |                        |            |            |  |
|                       | DNEL  | Short term                              | 442 mg/m <sup>3</sup>  | Workers    | Local      |  |
|                       |       | Inhalation                              |                        |            |            |  |
|                       | DNEL  | Short term                              | 442 mg/m <sup>3</sup>  | Workers    | Systemic   |  |
|                       |       | Inhalation                              |                        |            |            |  |
| 2-butoxyethyl acetate | DNEL  | Long term Oral                          | 8.6 mg/kg              | General    | Systemic   |  |
|                       |       |   | bw/day                 | population |            |  |
|                       | DNEL  | Short term Oral                         | 36 mg/kg               | General    | Systemic   |  |
|                       |       |   | bw/day                 | population |            |  |
|                       | DNEL  | Short term Dermal                       | 72 mg/kg               | General    | Systemic   |  |
|                       |       |   | bw/day                 | population |            |  |
|                       | DNEL  | Long term                               | 80 mg/m <sup>3</sup>   | General    | Systemic   |  |
|                       |       | Inhalation                              |                        | population |            |  |
|                       | DNEL  | Long term Dermal                        | 102 mg/kg              | General    | Systemic   |  |
|                       |       | 5                                       | bw/day                 | population | ,          |  |
|                       | DNEL  | Short term Dermal                       | 120 mg/kg              | Workers    | Systemic   |  |
|                       | 0.122 | ener term berna                         | bw/day                 | T officero | eyetenne   |  |
|                       | DNEL  | Long term                               | 133 mg/m <sup>3</sup>  | Workers    | Systemic   |  |
|                       |       | Inhalation                              | roo mg/m               | Workere    | Cyclonic   |  |
|                       | DNEL  | Long term Dermal                        | 169 mg/kg              | Workers    | Systemic   |  |
|                       |       |   | bw/day                 |            | Cystomic   |  |
|                       | DNEL  | Short term                              | 200 mg/m <sup>3</sup>  | General    | Local      |  |
|                       |       | Inhalation                              | 200 mg/m               | population | Luca       |  |
|                       |       |   | 222 malm3              |            | Loop       |  |
|                       | DNEL  | Short term                              | 333 mg/m <sup>3</sup>  | Workers    | Local      |  |
|                       |       | Inhalation                              | 1.0                    | Comercia   | 0          |  |
| Ethylbenzene          | DNEL  | Long term Oral                          | 1.6 mg/kg              | General    | Systemic   |  |
|                       |       |   | bw/day                 | population |            |  |
|                       | DNEL  | Long term                               | 15 mg/m³               | General    | Systemic   |  |
|                       |       | Inhalation                              |                        | population |            |  |
|                       |       | 4 · · · · · · · · · · · · · · · · · · · |                        |            |            |  |

ALPOLAN DUOFINISH 5461-80 - FARBLOS-INCOLORE-COLOURLESS

|                     | DNEL  | Long term                | 77 mg/m <sup>3</sup>   | Workers               | Systemic |
|---------------------|-------|--------------------------|------------------------|-----------------------|----------|
|                     | DINLL | Inhalation               | rr mg/m                | VIOREIS               | Systemic |
|                     | DNEL  | Long term Dermal         | 180 mg/kg<br>bw/day    | Workers               | Systemic |
|                     | DNEL  | Short term<br>Inhalation | 293 mg/m <sup>3</sup>  | Workers               | Local    |
|                     | DMEL  | Long term<br>Inhalation  | 442 mg/m³              | Workers               | Local    |
|                     | DMEL  | Short term<br>Inhalation | 884 mg/m³              | Workers               | Systemic |
| Methyl methacrylate | DNEL  | Long term Oral           | 8.2 mg/kg<br>bw/day    | General<br>population | Systemic |
|                     | DNEL  | Short term<br>Inhalation | 208 mg/m <sup>3</sup>  | General population    | Local    |
|                     | DNEL  | Short term<br>Inhalation | 416 mg/m <sup>3</sup>  | Workers               | Local    |
|                     | DNEL  | Short term Dermal        | 1.5 mg/cm <sup>2</sup> | population            | Local    |
|                     | DNEL  | Long term Dermal         | 1.5 mg/cm <sup>2</sup> | General population    | Local    |
|                     | DNEL  | Short term Dermal        | 1.5 mg/cm <sup>2</sup> | Workers               | Local    |
|                     | DNEL  | Long term Dermal         | 1.5 mg/cm <sup>2</sup> | Workers               | Local    |
|                     | DNEL  | Long term Dermal         | 8.2 mg/kg<br>bw/day    | General<br>population | Systemic |
|                     | DNEL  | Long term Dermal         | 13.67 mg/<br>kg bw/day | Workers               | Systemic |
|                     | DNEL  | Long term<br>Inhalation  | 74.3 mg/m <sup>3</sup> | General<br>population | Systemic |
|                     | DNEL  | Long term<br>Inhalation  | 104 mg/m³              | General<br>population | Local    |
|                     | DNEL  | Long term<br>Inhalation  | 208 mg/m <sup>3</sup>  | Workers               | Local    |
|                     | DNEL  | Long term<br>Inhalation  | 348.4 mg/<br>m³        | Workers               | Systemic |

### **PNECs**

No PNECs available

| 8.2 Exposure controls<br>Appropriate engineering<br>controls | :   | Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapour or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.  |
|--|-----|---|
| Individual protection measur                                 | res |   |
| Hygiene measures   | :   | Wash hands, forearms and face thoroughly after handling chemical products,<br>before eating, smoking and using the lavatory and at the end of the working period.<br>Appropriate techniques should be used to remove potentially contaminated clothing.<br>Contaminated work clothing should not be allowed out of the workplace. Wash<br>contaminated clothing before reusing. Ensure that eyewash stations and safety<br>showers are close to the workstation location. |
| Eye/face protection  | :   | Safety eyewear complying with an approved standard should be used when a risk<br>assessment indicates this is necessary to avoid exposure to liquid splashes, mists,<br>gases or dusts. If contact is possible, the following protection should be worn,<br>unless the assessment indicates a higher degree of protection: chemical splash<br>goggles.  |
| Skin protection  |     |   |

### **SECTION 8: Exposure controls/personal protection**

| Hand protection                 | <ul> <li>Chemical-resistant, impervious gloves complying with an approved standard should<br/>be worn at all times when handling chemical products if a risk assessment indicates<br/>this is necessary. Considering the parameters specified by the glove manufacturer,<br/>check during use that the gloves are still retaining their protective properties. It<br/>should be noted that the time to breakthrough for any glove material may be<br/>different for different glove manufacturers. In the case of mixtures, consisting of<br/>several substances, the protection time of the gloves cannot be accurately<br/>estimated.</li> </ul> |
|---------------------------------|--|
|                                 | Recommendations : Wear suitable gloves tested to EN374.  |
|                                 | < 1 hour (breakthrough time): Nitrile gloves. thickness > 0.3 mm   |
|                                 | 1 - 4 hours (breakthrough time): 4H / Silver Shield® gloves.   |
| Body protection                 | : Personal protective equipment for the body should be selected based on the task<br>being performed and the risks involved and should be approved by a specialist<br>before handling this product. When there is a risk of ignition from static electricity,<br>wear anti-static protective clothing. For the greatest protection from static<br>discharges, clothing should include anti-static overalls, boots and gloves. Refer to<br>European Standard EN 1149 for further information on material and design<br>requirements and test methods.   |
| Other skin protection           | <ul> <li>Appropriate footwear and any additional skin protection measures should be<br/>selected based on the task being performed and the risks involved and should be<br/>approved by a specialist before handling this product.</li> </ul>  |
| Respiratory protection          | <ul> <li>Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.</li> <li>Filter type: A</li> </ul>   |
|                                 | Filter type (spray application): A P   |
| Environmental exposure controls | : Emissions from ventilation or work process equipment should be checked to<br>ensure they comply with the requirements of environmental protection legislation.<br>In some cases, fume scrubbers, filters or engineering modifications to the process<br>equipment will be necessary to reduce emissions to acceptable levels.  |

### **SECTION 9: Physical and chemical properties**

The conditions of measurement of all properties are at standard temperature and pressure unless otherwise indicated.

#### 9.1 Information on basic physical and chemical properties

| <u>Appearance</u>            |                  |
|------------------------------|------------------|
| Physical state               | : Liquid.        |
| Colour                       | : Colourless.    |
| Odour                        | : Slight         |
| Odour threshold              | : Not available. |
| Melting point/freezing point | : Not available. |
| Initial boiling point and    | :                |
| boiling range                |                  |
|                              |                  |

| Ingredient name | °C    | °F    | Method |
|-----------------|-------|-------|--------|
| Ethyl acetate   | 77.1  | 170.8 |        |
| Toluene         | 110.6 | 231.1 |        |

| Flammability                    | 1 | Not available.                                       |
|---------------------------------|---|--|
| Lower and upper explosion limit | : | Lower: 0.8% (xylene)<br>Upper: 11.5% (ethyl acetate) |
| Flash point                     | : | Closed cup: -1°C (30.2°F)                            |
| Auto-ignition temperature       | : |  |

| Ingredient name       | °C  | °F  | Method  |
|-----------------------|-----|-----|---------|
| 2-butoxyethyl acetate | 340 | 644 |         |
| n-Butyl acetate       | 415 | 779 | EU A.15 |

Date of issue/Date of revision: 26/09/2024Date of previous issueALPOLAN DUOFINISH 5461-80 - FARBLOS-INCOLORE-COLOURLESS

No previous validation

Version :1 11/20

Label No :51674

### **SECTION 9: Physical and chemical properties**

2

| Decomposition temperature                  | 1 | Not available.  |
|--|---|-----------------|
| рН   | : | Not applicable. |
| Viscosity                                  | ; | Not available.  |
| Solubility(ies)                            | : |                 |
| Not available.                             |   |                 |
| Solubility in water                        | : | Not available.  |
| Partition coefficient: n-octanol/<br>water | : | Not applicable. |

### Vapour pressure

|                          | Va       | apour Press | ure at 20°C | Vapour pressure at 50 |     |        |
|--------------------------|----------|-------------|-------------|-----------------------|-----|--------|
| Ingredient name          | mm Hg    | kPa         | Method      | mm Hg                 | kPa | Method |
| Ethyl acetate            | 81.59163 | 10.9        |             |                       |     |        |
| Toluene                  | 23.17    | 3.1         |             |                       |     |        |
| Relative density         | : Not    | available.  |             |                       |     |        |
| Density                  | : 0.9    | g/cm³       |             |                       |     |        |
| Vapour density           | : Not    | available.  |             |                       |     |        |
| Explosive properties     | : Not    | available.  |             |                       |     |        |
| Oxidising properties     | : Not    | available.  |             |                       |     |        |
| Particle characteristics |          |             |             |                       |     |        |
| Median particle size     | : Not    | applicable. |             |                       |     |        |

#### 9.2 Other information

No additional information.

### **SECTION 10: Stability and reactivity**

| 10.1 Reactivity                            | : | No specific test data related to reactivity available for this product or its ingredients.  |
|--|---|---|
| 10.2 Chemical stability                    | : | The product is stable.  |
| 10.3 Possibility of<br>hazardous reactions | : | Under normal conditions of storage and use, hazardous reactions will not occur.   |
| 10.4 Conditions to avoid                   | : | Avoid all possible sources of ignition (spark or flame). Do not pressurise, cut, weld, braze, solder, drill, grind or expose containers to heat or sources of ignition. |
| 10.5 Incompatible materials                | : | Reactive or incompatible with the following materials:<br>oxidising materials   |
| 10.6 Hazardous<br>decomposition products   | : | Under normal conditions of storage and use, hazardous decomposition products should not be produced.  |

### **SECTION 11: Toxicological information**

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008 Acute toxicity

12/20

## SECTION 11: Toxicological information

| Product/ingredient name | Result                    | Species | Dose                    | Exposure |
|-------------------------|---------------------------|---------|-------------------------|----------|
| n-Butyl acetate         | LC50 Inhalation Vapour    | Rat     | 0.74 mg/l               | 4 hours  |
| -                       | LD50 Dermal               | Rabbit  | 14112 mg/kg             | -        |
|                         | LD50 Oral                 | Rat     | 10760 mg/kg             | -        |
| Ethyl acetate           | LD50 Oral                 | Rat     | 5620 mg/kg              | -        |
| Toluene                 | LC50 Inhalation Vapour    | Rat     | 49 g/m <sup>3</sup>     | 4 hours  |
|                         | LD50 Oral                 | Rat     | 636 mg/kg               | -        |
| Xylene                  | LC50 Inhalation Vapour    | Rat     | 21.7 mg/l               | 4 hours  |
| -                       | LD50 Oral                 | Rat     | 4300 mg/kg              | -        |
| 2-butoxyethyl acetate   | LD50 Dermal               | Rabbit  | 1500 mg/kg              | -        |
|                         | LD50 Oral                 | Rat     | 2400 mg/kg              | -        |
| Ethylbenzene            | LC50 Inhalation Dusts and | Rat     | 29000 mg/l              | 4 hours  |
|                         | mists                     |         |                         |          |
|                         | LD50 Dermal               | Rabbit  | 15400 mg/kg             | -        |
|                         | LD50 Oral                 | Rat     | 3500 mg/kg              | -        |
| Methyl methacrylate     | LC50 Inhalation Vapour    | Rat     | 78000 mg/m <sup>3</sup> | 4 hours  |
| · ·                     | LD50 Dermal               | Rabbit  | >5 g/kg                 | -        |
|                         | LD50 Oral                 | Rat     | 7872 mg/kg              | -        |

### Conclusion/Summary

: Based on available data, the classification criteria are not met.

### Acute toxicity estimates

| Route | ATE value                    |  |
|-------|------------------------------|--|
|       | 11213.45 mg/kg<br>90.53 mg/l |  |

### Irritation/Corrosion

| Product/ingredient name | Result  | Species          | Score       | Exposure         | Observation |  |  |
|-------------------------|---|------------------|-------------|------------------|-------------|--|--|
| n-Butyl acetate         | Eyes - Moderate irritant  | Rabbit           | -           | 100 mg           | -           |  |  |
| -                       | Skin - Moderate irritant  | Rabbit           | -           | 24 hours 500     | -           |  |  |
| <u> </u>                |   |                  |             | mg               |             |  |  |
| Toluene                 | Eyes - Mild irritant  | Rabbit           | -           | 0.5 minutes      | -           |  |  |
|                         | Eyes - Mild irritant  | Rabbit           | _           | 100 mg<br>870 ug | _           |  |  |
|                         | Eyes - Severe irritant  | Rabbit           | _           | 24 hours 2       | -           |  |  |
|                         |   |                  |             | mg               |             |  |  |
|                         | Skin - Mild irritant  | Pig              | -           | 24 hours 250     | -           |  |  |
|                         |   |                  |             | uL               |             |  |  |
|                         | Skin - Mild irritant  | Rabbit           | -           | 435 mg           | -           |  |  |
|                         | Skin - Moderate irritant  | Rabbit           | -           | 24 hours 20      | -           |  |  |
|                         | Skin - Moderate irritant  | Rabbit           | _           | mg<br>500 mg     | _           |  |  |
| Xylene                  | Eyes - Mild irritant  | Rabbit           | -           | 87 mg            | -           |  |  |
| ,<br>,                  | Eyes - Severe irritant  | Rabbit           | -           | 24 hours 5       | -           |  |  |
|                         |   |                  |             | mg               |             |  |  |
|                         | Skin - Mild irritant  | Rat              | -           | 8 hours 60 uL    | -           |  |  |
|                         | Skin - Moderate irritant  | Rabbit           | -           | 100 %            | -           |  |  |
|                         | Skin - Moderate irritant  | Rabbit           | -           | 24 hours 500     | -           |  |  |
| 2-butoxyethyl acetate   | Eyes - Mild irritant  | Rabbit           | _           | 24 hours 500     | -           |  |  |
|                         |   | T CODDIT         |             | mg               |             |  |  |
|                         | Skin - Mild irritant  | Rabbit           | -           | 500 mg           | -           |  |  |
| Ethylbenzene            | Eyes - Severe irritant  | Rabbit           | -           | 500 mg           | -           |  |  |
|                         | Skin - Mild irritant  | Rabbit           | -           | 24 hours 15      | -           |  |  |
|                         |   |                  |             | mg               |             |  |  |
| Conclusion/Summary      | : Causes skin irritation.   |                  |             |                  |             |  |  |
| <u>Sensitisation</u>    |   |                  |             |                  |             |  |  |
| Conclusion/Summary      | : May cause an allergic skin re                                     | action.          |             |                  |             |  |  |
| Mutagenicity            | -   |                  |             |                  |             |  |  |
| Conclusion/Summary      | : Based on available data, the                                      | classification c | riteria are | not met.         |             |  |  |
| Carcinogenicity         | : Based on available data, the classification criteria are not met. |                  |             |                  |             |  |  |
| Conclusion/Summary      | · Rasad on available data the                                       | classification o | ritoria ara | not mot          |             |  |  |
| conclusion/summary      | : Based on available data, the                                      | Classification C | nteria ale  | not met.         |             |  |  |

Date of issue/Date of revision: 26/09/2024Date of previous issue: No previous validationVersion: 113/20ALPOLAN DUOFINISH 5461-80 - FARBLOS-INCOLORE-COLOURLESSLabel No :51674

### **SECTION 11: Toxicological information**

### **Reproductive toxicity**

### **Conclusion/Summary**

: Based on available data, the classification criteria are not met.

### **Teratogenicity**

**Conclusion/Summary** : Suspected of damaging the unborn child.

### Specific target organ toxicity (single exposure)

| Product/ingredient name | Category   | Route of exposure | Target organs                |
|-------------------------|------------|-------------------|------------------------------|
| n-Butyl acetate         | Category 3 | -                 | Narcotic effects             |
| Ethyl acetate           | Category 3 | -                 | Narcotic effects             |
| Toluene                 | Category 3 | -                 | Narcotic effects             |
| Xylene                  | Category 3 | -                 | Respiratory tract irritation |
| Methyl methacrylate     | Category 3 | -                 | Respiratory tract irritation |

#### Specific target organ toxicity (repeated exposure)

| Product/ingredient name | Category   | Route of exposure | Target organs  |
|-------------------------|------------|-------------------|----------------|
| Toluene                 | Category 2 | -                 | -              |
| Xylene                  | Category 2 | oral, inhalation  | -              |
| Ethylbenzene            | Category 2 | oral, inhalation  | hearing organs |

#### **Aspiration hazard**

| Product/ingredient name | Result                         |
|-------------------------|--------------------------------|
| Toluene                 | ASPIRATION HAZARD - Category 1 |
| Xylene                  | ASPIRATION HAZARD - Category 1 |
| Ethylbenzene            | ASPIRATION HAZARD - Category 1 |

### Information on likely routes : Not available.

### of exposure

| Potential acute health | <u>effects</u>  |
|------------------------|---|
| Eye contact            | : Causes serious eye irritation.  |
| Inhalation             | : Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness. |
| Skin contact           | : Causes skin irritation. May cause an allergic skin reaction.                          |
| Ingestion              | : Can cause central nervous system (CNS) depression.                                    |

#### Symptoms related to the physical, chemical and toxicological characteristics

| Eye contact  | : Adverse symptoms may include the following:<br>pain or irritation<br>watering<br>redness  |
|--------------|---|
| Inhalation   | : Adverse symptoms may include the following:<br>nausea or vomiting<br>headache<br>drowsiness/fatigue<br>dizziness/vertigo<br>unconsciousness<br>reduced foetal weight<br>increase in foetal deaths<br>skeletal malformations |
| Skin contact | : Adverse symptoms may include the following:<br>irritation<br>redness<br>reduced foetal weight<br>increase in foetal deaths<br>skeletal malformations  |

| <b>SECTION 11: Toxico</b>    | lo  | gical information  |
|------------------------------|-----|--|
| Ingestion                    | :   | Adverse symptoms may include the following:<br>reduced foetal weight<br>increase in foetal deaths<br>skeletal malformations  |
| Delayed and immediate effect | :ts | as well as chronic effects from short and long-term exposure   |
| Short term exposure          |     |  |
| Potential immediate effects  | :   | Not available.   |
| Potential delayed effects    | 1   | Not available.   |
| <u>Long term exposure</u>    |     |  |
| Potential immediate effects  | 1   | Not available.   |
| Potential delayed effects    | :   | Not available.   |
| Potential chronic health eff | ect | <u>s</u>   |
| Not available.               |     |  |
| Conclusion/Summary           | :   | Not available.   |
| General                      | :   | May cause damage to organs through prolonged or repeated exposure. Once sensitized, a severe allergic reaction may occur when subsequently exposed to very low levels. |
| Carcinogenicity              | 1   | No known significant effects or critical hazards.  |
| Mutagenicity                 | :   | No known significant effects or critical hazards.  |
| Reproductive toxicity        | :   | Suspected of damaging the unborn child.  |

#### 11.2 Information on other hazards

### 11.2.1 Endocrine disrupting properties

Not available.

### 11.2.2 Other information

Not available.

## **SECTION 12: Ecological information**

### 12.1 Toxicity

| Product/ingredient name | Result  | Species  | Exposure |
|-------------------------|---|--|----------|
| n-Butyl acetate         | Acute LC50 32 mg/l Marine water               | Crustaceans - Artemia salina                                   | 48 hours |
|                         | Acute LC50 18000 µg/l Fresh water             | Fish - Pimephales promelas                                     | 96 hours |
| Ethyl acetate           | Acute EC50 2500000 µg/l Fresh water           | Algae - Selenastrum sp.  | 96 hours |
|                         | Acute LC50 750000 µg/l Fresh water            | Crustaceans - Gammarus pulex                                   | 48 hours |
|                         | Acute LC50 154000 µg/l Fresh water            | Daphnia - Daphnia cucullata                                    | 48 hours |
|                         | Acute LC50 212500 µg/l Fresh water            | Fish - Heteropneustes fossilis                                 | 96 hours |
|                         | Chronic NOEC 12 mg/l Fresh water              | Daphnia - <i>Daphnia magna</i>                                 | 21 days  |
|                         | Chronic NOEC 75.6 mg/l Fresh water            | Fish - Pimephales promelas -                                   | 32 days  |
|                         |   | Embryo   |          |
| Toluene                 | Acute EC50 12500 μg/l Fresh water             | Algae - Pseudokirchneriella<br>subcapitata                     | 72 hours |
|                         | Acute EC50 11600 µg/l Fresh water             | Crustaceans - <i>Gammarus</i><br><i>pseudolimnaeus</i> - Adult | 48 hours |
|                         | Acute EC50 5.56 mg/l Fresh water              | Daphnia - <i>Daphnia magna</i> -<br>Neonate                    | 48 hours |
|                         | Acute LC50 5500 μg/l Fresh water              | Fish - Oncorhynchus kisutch -<br>Fry                           | 96 hours |
|                         | Chronic NOEC 1000 µg/l Fresh water            | Daphnia - <i>Daphnia magna</i>                                 | 21 days  |
| Methyl methacrylate     | Acute LC50 130000 µg/l Fresh water            | Fish - <i>Pimephales promelas</i> - Adult                      | 96 hours |
| Conclusion/Summary      | : Based on available data, the classification | ation criteria are not met.                                    | •        |

### 12.2 Persistence and degradability

| Date of issue/Date of revision | : 26/09/2024 | Date of previous issue | : No previous validation | Version  | :1     | 15/20 |
|--------------------------------|--------------|------------------------|--------------------------|----------|--------|-------|
| ALPOLAN DUOFINISH 5461-80 -    | FARBLOS-I    | NCOLORE-COLOURLESS     |                          | Label No | :51674 | 4     |

### **SECTION 12: Ecological information**

**Conclusion/Summary** 

: This product has not been tested for biodegradation.

### 12.3 Bioaccumulative potential

| Product/ingredient name | LogPow | BCF         | Potential |
|-------------------------|--------|-------------|-----------|
| n-Butyl acetate         | 2.3    | -           | Low       |
| Ethyl acetate           | 0.68   | 30          | Low       |
| Toluene                 | 2.73   | 90          | Low       |
| Xylene                  | 3.12   | 8.1 to 25.9 | Low       |
| 2-butoxyethyl acetate   | 1.51   | -           | Low       |
| Ethylbenzene            | 3.6    | -           | Low       |
| Methyl methacrylate     | 1.38   | -           | Low       |

### 12.4 Mobility in soil

| Soil/water partition | : Not available. |
|----------------------|------------------|
| coefficient (Koc)    |                  |
| Mobility             | : Not available. |

### 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

### 12.6 Endocrine disrupting properties

Not available.

#### 12.7 Other adverse effects

No known significant effects or critical hazards.

### **SECTION 13: Disposal considerations**

#### **13.1 Waste treatment methods**

| Product                           |   |
|-----------------------------------|---|
| Methods of disposal               | : The generation of waste should be avoided or minimised wherever possible.<br>Disposal of this product, solutions and any by-products should at all times comply<br>with the requirements of environmental protection and waste disposal legislation and<br>any regional local authority requirements. Dispose of surplus and non-recyclable<br>products via a licensed waste disposal contractor. Waste should not be disposed of<br>untreated to the sewer unless fully compliant with the requirements of all authorities<br>with jurisdiction. |
| European waste<br>catalogue (EWC) | : 08.01.11  |
| Packaging                         |   |
| Methods of disposal               | : The generation of waste should be avoided or minimised wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered when recycling is not feasible.  |
| Special precautions               | : This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapour from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilt material and runoff and contact with soil, waterways, drains and sewers.         |

|  | ADR/RID  | ADN   | IMDG   | ΙΑΤΑ   |
|--|--|---|--|--|
| 14.1 UN number<br>or ID number                             | UN1993   | UN1993  | UN1993   | UN1993   |
| 14.2 UN proper<br>shipping name                            | FLAMMABLE LIQUID,<br>N.O.S. (n-butyl<br>acetate, ethyl acetate)    | FLAMMABLE LIQUID,<br>N.O.S. (n-butyl<br>acetate, ethyl acetate)                                     | FLAMMABLE LIQUID,<br>N.O.S. (ethyl acetate,<br>xylene) | FLAMMABLE LIQUID,<br>N.O.S. (ethyl acetate,<br>xylene) |
| 14.3 Transport<br>hazard class(es)                         | 3  | 3   | 3  | 3  |
| 14.4 Packing<br>group                                      | 11   | II  | II   | 11   |
| 14.5<br>Environmental<br>hazards                           | No.  | Yes.  | No.  | No.  |
| Additional information ADR/RID                             | : <u>Special pro<br/>Tunnel coo</u><br>: The produc<br>transported | ovisions 640 (C)<br>de (D/E)<br>t is only regulated as an<br>l in tank vessels.<br>ovisions 640 (C) | environmentally hazardo                                | ous substance when                                     |
| 14.6 Special precau<br>user                                | upright and  | within user's premises<br>I secure. Ensure that per<br>f an accident or spillage.                   | sons transporting the pro                              |  |
| 14.7 Maritime trans<br>bulk according to II<br>instruments |  | nt/applicable due to natur  | e of the product.                                      |  |

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture <u>EU Regulation (EC) No. 1907/2006 (REACH)</u>

Annex XIV - List of substances subject to authorisation

ŝ

Annex XIV

None of the components are listed.

#### Substances of very high concern

None of the components are listed.

### <u>Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous</u> <u>substances, mixtures and articles</u>

| Product/ingredient name   | %         | Designation [Usage] |
|---------------------------|-----------|---------------------|
| ALPOLAN DUOFINISH 5461-80 | ≥90       | 3                   |
| Toluene                   | ≥10 - ≤25 | 48                  |

#### Labelling

Other EU regulations

Industrial emissions : Not listed (integrated pollution prevention and control) -Air

### **SECTION 15: Regulatory information**

| Industrial emissions : Not listed<br>(integrated pollution<br>prevention and control) -<br>Water |
|--|
| Explosive precursors : Not applicable.   |
| Ozone depleting substances (1005/2009/EU)  |
| Not listed.  |
| Prior Informed Consent (PIC) (649/2012/EU)   |
| Not listed.  |
| Persistent Organic Pollutants<br>Not listed.   |
| Seveso Directive   |
| This product is controlled under the Seveso Directive.   |
| Danger criteria  |
| Category   |
|  |
| P5c  |
| International regulations  |
| Chemical Weapon Convention List Schedules I, II & III Chemicals                                  |
| Not listed.  |
| Montreal Protocol  |
| Not listed.  |
| Stockholm Convention on Persistent Organic Pollutants  |
| Not listed.  |
| Rotterdam Convention on Prior Informed Consent (PIC)<br>Not listed.                              |

#### **UNECE Aarhus Protocol on POPs and Heavy Metals**

Not listed.

**15.2 Chemical safety assessment** : This product contains substances for which Chemical Safety Assessments are still required.

### **SECTION 16: Other information**

Indicates information that has changed from previously issued version.

| Abbreviations and acronyms    | <ul> <li>ATE = Acute Toxicity Estimate<br/>CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No.<br/>1272/2008]<br/>DMEL = Derived Minimal Effect Level</li> </ul> |
|-------------------------------|--|
|                               | DNEL = Derived Norman Effect Level   |
|                               | EUH statement = CLP-specific Hazard statement  |
|                               | N/A = Not available  |
|                               | PBT = Persistent, Bioaccumulative and Toxic  |
|                               | PNEC = Predicted No Effect Concentration   |
|                               | RRN = REACH Registration Number  |
|                               | SGG = Segregation Group  |
|                               | vPvB = Very Persistent and Very Bioaccumulative  |
| Due a selection and the sheet | the close disection according to Deputcien (50) No. 4070/0000 (01 D/01/01  |

Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

|   | Other information  |                                       |
|---|--|---------------------------------------|
| Classification  |  | Justification                         |
| Flam. Liq. 2, H225  |  | On basis of test data                 |
| Skin Irrit. 2, H315   |  | Calculation method                    |
| Eye Irrit. 2, H319  |  | Calculation method                    |
| Skin Sens. 1, H317  |  | Calculation method                    |
| Repr. 2, H361d  |  | Calculation method                    |
| STOT SE 3, H336   |  | Calculation method                    |
| STOT RE 2, H373   |  | Calculation method                    |
| Full text of abbrevia   | ted H statements   |                                       |
|   | ghly flammable liquid and vapour.  |                                       |
|   | Flammable liquid and vapour.   |                                       |
|   | ay be fatal if swallowed and enters airv   | Nays.                                 |
|   | Harmful in contact with skin.  |                                       |
|   | Causes skin irritation.  |                                       |
|   | May cause an allergic skin reaction.   |                                       |
|   | Causes serious eye irritation.   |                                       |
|   | rmful if inhaled.  |                                       |
|   | ay cause respiratory irritation.   |                                       |
|   | ay cause drowsiness or dizziness.  |                                       |
|   | spected of damaging the unborn child   |                                       |
|   | ay cause damage to organs through p  |                                       |
|   | xic to aquatic life with long lasting effe<br>peated exposure may cause skin dry |                                       |
|   |  |                                       |
| Full text of classific  |  |                                       |
| Acute Tox. 4  | ACUTE TOXICITY - Category 4  |                                       |
| Aquatic Chronic 2   | LONG-TERM (CHRONIC) AQUAT  |                                       |
| Asp. Tox. 1 ASPIRATION HAZARD - Category 1<br>Eye Irrit. 2 SERIOUS EYE DAMAGE/EYE IRRITATION - Category 2 |  |                                       |
| Flam. Liq. 2 FLAMMABLE LIQUIDS - Category 2   |  |                                       |
| Flam. Liq. 3 FLAMMABLE LIQUIDS - Category 3   |  |                                       |
| Repr. 2   | REPRODUCTIVE TOXICITY - Ca   |                                       |
| Skin Irrit. 2   |  |                                       |
| Skin Sens. 1  | SKIN SENSITISATION - Category 1  |                                       |
| Skin Sens. 1A   | SKIN SENSITISATION - Category 1A   |                                       |
| STOT RE 2   | SPECIFIC TARGET ORGAN TOXICITY - REPEATED EXPOSURE - Category 2                  |                                       |
| STOT SE 3   |  | (ICITY - SINGLE EXPOSURE - Category 3 |
| Date of issue/ Date   |  |                                       |
| revision  |  |                                       |
| Date of previous iss  | <b>Sue</b> : No previous validation  |                                       |
| Version   | : 1  |                                       |
|   | ALPOLAN DUOFINISH 5461-  |                                       |

#### Notice to reader

The information in this SDS is based on the present state of our knowledge and on current laws. The product is not to be used for purposes other than those specified under section 1 without first obtaining written handling instructions. It is always the responsibility of the user to take all necessary steps to fulfil the demands set out in the local rules and legislation. The information in this SDS is meant to be a description of the safety requirements for our product. It is not to be considered a guarantee of the product's properties.

Date of issue/Date of revision: 26/09/2024Date of previous issue: No previous validationVersion: 120/20ALPOLAN DUOFINISH 5461-80 - FARBLOS-INCOLORE-COLOURLESSLabel No :51674